[ Price : $8.95]
Cubist Pharmaceuticals plans Phase 3 clinical trials of its therapy to treat Clostridium difficile-associated diarrhea.[ Price : $8.95]
FDA and other regulatory and international partners complete a week-long Internet crackdown on producers and distributors of count...[ Price : $8.95]
FDA clears U.S. Army Office of the Surgeon General 510(k)s for two Influenza test kits and their use with Idaho Technology's Joint...[ Price : $8.95]
FDA warns two Internet marketers using hundreds of Web sites to market unapproved and misbranded prescription drugs.[ Price : $8.95]
CSL Biotherapies says it has received no new FDA warnings for its influenza vaccine manufacturing facility in Australia.[ Price : $8.95]
CDRH director Jeff Shuren tells AdvaMed 2011 that device reviewers need to clear with the Center Science Council any requests to r...[ Price : $8.95]
FDA declares complete a Discovery Laboratories response to the agencys complete response letter on Surfaxin, an investigational dr...[ Price : $8.95]
Federal Register Notice: FDA submits a proposed collection of information on the reporting and recordkeeping requirements containe...